AUTHOR=Gros Sebastien A. A. , Santhanam Anand P. , Block Alec M. , Emami Bahman , Lee Brian H. , Joyce Cara 

TITLE=Retrospective Clinical Evaluation of a Decision-Support Software for Adaptive Radiotherapy of Head and Neck Cancer Patients

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.777793

DOI=10.3389/fonc.2022.777793

ISSN=2234-943X

ABSTRACT=<sec><title>Purpose</title><p>This study aimed to evaluate the clinical need for an automated decision-support software platform for adaptive radiation therapy (ART) of head and neck cancer (HNC) patients.</p></sec><sec><title>Methods</title><p>We tested RTapp (SegAna), a new ART software platform for deciding when a treatment replan is needed, to investigate a set of 27 HNC patients’ data retrospectively. For each fraction, the software estimated key components of ART such as daily dose distribution and cumulative doses received by targets and organs at risk (OARs) from daily 3D imaging in real-time. RTapp also included a prediction algorithm that analyzed dosimetric parameter (DP) trends against user-specified thresholds to proactively trigger adaptive re-planning up to four fractions ahead. The DPs evaluated for ART were based on treatment planning dose constraints. Warning (V<sub>95</sub>&lt;95%) and adaptation (V<sub>95</sub>&lt;93%) thresholds were set for PTVs, while OAR adaptation dosimetric endpoints of +10% (DE<sub>10</sub>) were set for all D<sub>max</sub> and D<sub>mean</sub> DPs. Any threshold violation at end of treatment (EOT) triggered a review of the DP trends to determine the threshold-crossing fraction <bold><italic>Fx</italic></bold> when the violations occurred. The prediction model accuracy was determined as the difference between calculated and predicted DP values with 95% confidence intervals (CI<sub>95</sub>).</p></sec><sec><title>Results</title><p>RTapp was able to address the needs of treatment adaptation. Specifically, we identified 18/27 studies (67%) for violating PTV coverage or parotid D<sub>mean</sub> at EOT. Twelve PTVs had V<sub>95</sub>&lt;95% (mean coverage decrease of −6.8 ± 2.9%) including six flagged for adaptation at median <bold><italic>Fx</italic></bold>= 6 (range, 1–16). Seventeen parotids were flagged for exceeding D<sub>mean</sub> dose constraints with a median increase of +2.60 Gy (range, 0.99–6.31 Gy) at EOT, including nine with DP&gt;DE<sub>10</sub>. The differences between predicted and calculated PTV V<sub>95</sub> and parotid D<sub>mean</sub> was up to 7.6% (mean ± CI<sub>95</sub>, −2.7 ± 4.1%) and 5 Gy (mean ± CI<sub>95</sub>, 0.3 ± 1.6 Gy), respectively. The most accurate predictions were obtained closest to the threshold-crossing fraction. For parotids, the results showed that <bold><italic>Fx</italic></bold> ranged between fractions 1 and 23, with a lack of specific trend demonstrating that the need for treatment adaptation may be verified for every fraction.</p></sec><sec><title>Conclusion</title><p>Integrated in an ART clinical workflow, RTapp aids in predicting whether specific treatment would require adaptation up to four fractions ahead of time.</p></sec>